Contrasting MIRA Pharmaceuticals (MIRA) & Its Rivals

MIRA Pharmaceuticals (NASDAQ:MIRA) is one of 1,004 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare MIRA Pharmaceuticals to related companies based on the strength of its valuation, profitability, analyst recommendations, earnings, dividends, risk and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for MIRA Pharmaceuticals and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	0	0	0	0	N/A
MIRA Pharmaceuticals Competitors	6709	19268	45752	971	2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 76.43%. Given MIRA Pharmaceuticals’ peers higher probable upside, analysts plainly believe MIRA Pharmaceuticals has less favorable growth aspects than its peers.

Institutional and Insider Ownership

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 44.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.8% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares MIRA Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	-$11.98 million	-0.90
MIRA Pharmaceuticals Competitors	$1.70 billion	$153.70 million	-2.84

MIRA Pharmaceuticals’ peers have higher revenue and earnings than MIRA Pharmaceuticals. MIRA Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares MIRA Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-293.51%	-229.04%
MIRA Pharmaceuticals Competitors	-2,906.52%	-289.52%	-31.95%

Summary

MIRA Pharmaceuticals peers beat MIRA Pharmaceuticals on 7 of the 9 factors compared.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.